Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Sally Lyons Wyatt, from Data analytics company Circana, says GLP-1 potential users are only three percent more likely to buy ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how the next generation of “small ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

Tia Timmer was always “on the heavier side,” but her weight never held her back – until she had to keep up with two grandchildren.

Welcome to The Thin Line, The New York Post’s new series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations ...

GLP-1 medications can create opportunity for change—but environment determines what lasts. Discover how context shapes habits ...

As many as 12% of Americans are currently using GLP-1 medications such as Ozempic and Wegovy, according to one estimate.

U.S. airline companies stand to save hundreds of millions each year from Americans losing weight thanks to GLP-1 drugs, ...